Hot Features
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various me... XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -1.64609053498 | 2.43 | 2.4771 | 2.335 | 45568 | 2.40146887 | CS |
| 4 | -0.11 | -4.4 | 2.5 | 2.56 | 2.335 | 30201 | 2.43200127 | CS |
| 12 | 0.05 | 2.13675213675 | 2.34 | 2.65 | 2.175 | 34505 | 2.3999251 | CS |
| 26 | -0.2 | -7.72200772201 | 2.59 | 2.7296 | 2.175 | 39163 | 2.4400936 | CS |
| 52 | -0.53 | -18.1506849315 | 2.92 | 3.61 | 2.09 | 68851 | 2.67812191 | CS |
| 156 | -2.73 | -53.3203125 | 5.12 | 9.96 | 2.09 | 61146 | 4.57830385 | CS |
| 260 | -14.61 | -85.9411764706 | 17 | 18.46 | 2.09 | 65389 | 6.39766381 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.